Tag Archives: ruxolitinib

October, 2018

25 October
FDA Grants Priority Review to Incyte’s Ruxolitinib for Treatment of Patients with Acute Graft-Versus-Host Disease

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids. The FDA grants Priority Review …
Share

2 January
Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Jakafi for GVHD

December 30, 2016 04:15 PM Eastern Standard Time WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). “We are very …
Share

11 February
Incyte Discontinues Late-Stage Study of its Pancreatic Cancer Combo

WILMINGTON, Del.–(BUSINESS WIRE)–Feb. 11, 2016– Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after …
Share